Literature DB >> 35197607

Treatment of autosomal recessive hearing loss via in vivo CRISPR/Cas9-mediated optimized homology-directed repair in mice.

Xi Gu1,2,3,4, Xinde Hu5, Daqi Wang1,2,4, Zhijiao Xu1,2,4, Fang Wang1,2,4, Di Li6,7, Geng-Lin Li1,2,4, Hui Yang5, Huawei Li8,9,10,11, Erwei Zuo12, Yilai Shu13,14,15.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35197607      PMCID： PMC9253335          DOI： 10.1038/s41422-022-00624-y

Source DB:  PubMed          Journal:  Cell Res        ISSN： 1001-0602            Impact factor:   46.297


× No keyword cloud information.
  10 in total

Review 1.  The kelch repeat superfamily of proteins: propellers of cell function.

Authors:  J Adams; R Kelso; L Cooley
Journal:  Trends Cell Biol       Date:  2000-01       Impact factor: 20.808

Review 2.  Therapeutic genome editing: prospects and challenges.

Authors:  David Benjamin Turitz Cox; Randall Jeffrey Platt; Feng Zhang
Journal:  Nat Med       Date:  2015-02       Impact factor: 53.440

3.  Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9.

Authors:  Dominik Paquet; Dylan Kwart; Antonia Chen; Andrew Sproul; Samson Jacob; Shaun Teo; Kimberly Moore Olsen; Andrew Gregg; Scott Noggle; Marc Tessier-Lavigne
Journal:  Nature       Date:  2016-04-27       Impact factor: 49.962

4.  Homology-mediated end joining-based targeted integration using CRISPR/Cas9.

Authors:  Xuan Yao; Xing Wang; Xinde Hu; Zhen Liu; Junlai Liu; Haibo Zhou; Xiaowen Shen; Yu Wei; Zijian Huang; Wenqin Ying; Yan Wang; Yan-Hong Nie; Chen-Chen Zhang; Sanlan Li; Leping Cheng; Qifang Wang; Yan Wu; Pengyu Huang; Qiang Sun; Linyu Shi; Hui Yang
Journal:  Cell Res       Date:  2017-05-19       Impact factor: 25.617

5.  Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents.

Authors:  Xue Gao; Yong Tao; Veronica Lamas; Mingqian Huang; Wei-Hsi Yeh; Bifeng Pan; Yu-Juan Hu; Johnny H Hu; David B Thompson; Yilai Shu; Yamin Li; Hongyang Wang; Shiming Yang; Qiaobing Xu; Daniel B Polley; M Charles Liberman; Wei-Jia Kong; Jeffrey R Holt; Zheng-Yi Chen; David R Liu
Journal:  Nature       Date:  2017-12-20       Impact factor: 49.962

6.  Screened AAV variants permit efficient transduction access to supporting cells and hair cells.

Authors:  Xinde Hu; Jinghan Wang; Xuan Yao; Qingquan Xiao; Yuanyuan Xue; Shaoran Wang; Linyu Shi; Yilai Shu; Huawei Li; Hui Yang
Journal:  Cell Discov       Date:  2019-10-15       Impact factor: 10.849

7.  Inner hair cell dysfunction in Klhl18 mutant mice leads to low frequency progressive hearing loss.

Authors:  Neil J Ingham; Navid Banafshe; Clarisse Panganiban; Julia L Crunden; Jing Chen; Morag A Lewis; Karen P Steel
Journal:  PLoS One       Date:  2021-10-01       Impact factor: 3.240

8.  A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice.

Authors:  Yang Yang; Lili Wang; Peter Bell; Deirdre McMenamin; Zhenning He; John White; Hongwei Yu; Chenyu Xu; Hiroki Morizono; Kiran Musunuru; Mark L Batshaw; James M Wilson
Journal:  Nat Biotechnol       Date:  2016-02-01       Impact factor: 54.908

9.  Correction of the auditory phenotype in C57BL/6N mice via CRISPR/Cas9-mediated homology directed repair.

Authors:  Joffrey Mianné; Lauren Chessum; Saumya Kumar; Carlos Aguilar; Gemma Codner; Marie Hutchison; Andrew Parker; Ann-Marie Mallon; Sara Wells; Michelle M Simon; Lydia Teboul; Steve D M Brown; Michael R Bowl
Journal:  Genome Med       Date:  2016-02-15       Impact factor: 11.117

10.  Genetic Hearing Loss and Gene Therapy.

Authors:  Nathanial T Carpena; Min Young Lee
Journal:  Genomics Inform       Date:  2018-12-28
  10 in total
  1 in total

1.  Precise detection of CRISPR-Cas9 editing in hair cells in the treatment of autosomal dominant hearing loss.

Authors:  Chong Cui; Daqi Wang; Bowei Huang; Fang Wang; Yuxin Chen; Jun Lv; Luping Zhang; Lei Han; Dong Liu; Zheng-Yi Chen; Geng-Lin Li; Huawei Li; Yilai Shu
Journal:  Mol Ther Nucleic Acids       Date:  2022-07-20       Impact factor: 10.183
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.